7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Uremia D014511 33 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Neoplasms, Experimental D009374 10 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lung Neoplasms D008175 171 associated lipids
Wounds and Injuries D014947 20 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Inflammation D007249 119 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Nephropathies D003928 39 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Mandibular Diseases D008336 5 associated lipids
Bone Resorption D001862 7 associated lipids
Foreign-Body Reaction D005549 10 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Bone Neoplasms D001859 5 associated lipids
Fractures, Bone D050723 4 associated lipids
Osteoarthritis D010003 4 associated lipids
Carcinoma D002277 18 associated lipids
Osteonecrosis D010020 5 associated lipids
Heart Failure D006333 36 associated lipids
Arthritis, Rheumatoid D001172 3 associated lipids
Osteitis D010000 10 associated lipids
Coronary Disease D003327 70 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Osteosarcoma D012516 50 associated lipids
Hip Fractures D006620 2 associated lipids
Osteolysis D010014 8 associated lipids
Hypothyroidism D007037 32 associated lipids
Osteoarthritis, Hip D015207 4 associated lipids
Vision Disorders D014786 10 associated lipids
Multiple Myeloma D009101 13 associated lipids
Osteoporosis D010024 12 associated lipids
Kidney Diseases D007674 29 associated lipids
Weight Gain D015430 101 associated lipids
Otosclerosis D010040 2 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Calcinosis D002114 5 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Bone Diseases, Metabolic D001851 9 associated lipids
Adrenal Hyperplasia, Congenital D000312 2 associated lipids
Obesity D009765 29 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Endometriosis D004715 29 associated lipids
Myocardial Infarction D009203 21 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Alzheimer Disease D000544 76 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Malocclusion D008310 3 associated lipids
Arteriosclerosis D001161 86 associated lipids
Leukemia D007938 74 associated lipids
Neuroblastoma D009447 66 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Periodontal Diseases D010510 15 associated lipids
Osteitis Deformans D010001 3 associated lipids
Dental Pulp Necrosis D003790 6 associated lipids
Crohn Disease D003424 12 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Fractures, Stress D015775 2 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
Thyroid Diseases D013959 8 associated lipids
Carcinoma, Ductal, Breast D018270 19 associated lipids
Myocardial Ischemia D017202 11 associated lipids
Paraneoplastic Syndromes D010257 4 associated lipids
Sepsis D018805 11 associated lipids
Periodontal Pocket D010514 9 associated lipids
Brain Infarction D020520 17 associated lipids
Hirsutism D006628 3 associated lipids
Polycystic Ovary Syndrome D011085 14 associated lipids
Hypocalcemia D006996 12 associated lipids
Brain Ischemia D002545 89 associated lipids
Endocrine System Diseases D004700 4 associated lipids
Nerve Degeneration D009410 53 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Hypertension D006973 115 associated lipids
Periodontitis D010518 22 associated lipids
Leukemia, Lymphocytic, Chronic, B-Cell D015451 25 associated lipids
Diabetic Angiopathies D003925 20 associated lipids
Polycythemia Vera D011087 13 associated lipids
Mucocutaneous Lymph Node Syndrome D009080 9 associated lipids
Hyperalgesia D006930 42 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Rheumatic Diseases D012216 7 associated lipids
Cardiomyopathies D009202 10 associated lipids
Disease Susceptibility D004198 12 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Mizukami J et al. Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. 2002 Mol. Cell. Biol. pmid:11809792
Mochizuki S et al. Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats. 2002 J. Bone Miner. Metab. pmid:11810411
Childs LM et al. In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. 2002 J. Bone Miner. Res. pmid:11811549
Holloway WR et al. Leptin inhibits osteoclast generation. 2002 J. Bone Miner. Res. pmid:11811550
Coen G et al. Serum osteoprotegerin and renal osteodystrophy. 2002 Nephrol. Dial. Transplant. pmid:11812872
Viereck V et al. Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. 2002 J. Cell. Biochem. pmid:11835398
Wise GE et al. Inhibition of osteoclastogenesis by the secretion of osteoprotegerin in vitro by rat dental follicle cells and its implications for tooth eruption. 2002 Arch. Oral Biol. pmid:11839361
Scatena M and Giachelli C The alpha(v)beta3 integrin, NF-kappaB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis. 2002 Trends Cardiovasc. Med. pmid:11852256
Hofbauer LC and Kühne CA Cytokine inhibition: a new therapeutic avenue for skeletal diseases. 2002 Drug Discov. Today pmid:11854049
Viereck V et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. 2002 Biochem. Biophys. Res. Commun. pmid:11855844
Romas E et al. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. 2002 Bone pmid:11856640
Theill LE et al. RANK-L and RANK: T cells, bone loss, and mammalian evolution. 2002 Annu. Rev. Immunol. pmid:11861618
Roux S et al. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. 2002 Am. J. Clin. Pathol. pmid:11863217
Green EA et al. Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. 2002 Immunity pmid:11869680
Faucheux C et al. Nuclear localization of type I parathyroid hormone/parathyroid hormone-related protein receptors in deer antler osteoclasts: evidence for parathyroid hormone-related protein and receptor activator of NF-kappaB-dependent effects on osteoclast formation in regenerating mammalian bone. 2002 J. Bone Miner. Res. pmid:11874237
Kazama JJ et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. 2002 Am. J. Kidney Dis. pmid:11877571
Haas M et al. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. 2002 Am. J. Kidney Dis. pmid:11877577
Feige U Osteoprotegerin. 2001 Ann. Rheum. Dis. pmid:11890662
Holen I et al. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. 2002 Cancer Res. pmid:11912131
Mori H et al. RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse. 2002 Histochem. Cell Biol. pmid:11914926
Goater JJ et al. Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. 2002 J. Orthop. Res. pmid:11918293
Roux S et al. RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. 2002 Br. J. Haematol. pmid:11918537
Oshiro T et al. Osteoclast induction in periodontal tissue during experimental movement of incisors in osteoprotegerin-deficient mice. 2002 Anat. Rec. pmid:11920384
Redlich K et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. 2002 Arthritis Rheum. pmid:11920416
Khosla S et al. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. 2002 J. Clin. Endocrinol. Metab. pmid:11932280
Kanematsu M et al. Vector-averaged gravity regulates gene expression of receptor activator of NF-kappaB (RANK) ligand and osteoprotegerin in bone marrow stromal cells via cyclic AMP/protein kinase A pathway. 2002 Bone pmid:11934645
Li X et al. Effects of prostaglandin E2 on gene expression in primary osteoblastic cells from prostaglandin receptor knockout mice. 2002 Bone pmid:11934647
Jain RG and Lenhard JM Select HIV protease inhibitors alter bone and fat metabolism ex vivo. 2002 J. Biol. Chem. pmid:11937496
Schoppet M et al. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. 2002 Arterioscler. Thromb. Vasc. Biol. pmid:11950689
Ariyasu T et al. Trehalose augments osteoprotegerin production in the FHs74Int human intestinal epithelial cell line. 2002 In Vitro Cell. Dev. Biol. Anim. pmid:11963965
Bateman TA and Countryman S Osteoprotegerin and bone loss associated with spaceflight. 2002 Drug Discov. Today pmid:11965392
Inoue D and Matsumoto T [Recent advances in basic research of bone metabolism]. 2002 Nippon Rinsho pmid:11979916
Suzuki Y et al. [Bone destruction and bone loss in rheumatoid arthritis--mechanism, prevention and treatment]. 2002 Nippon Rinsho pmid:11979937
Inoue D [Recent advances in research of bone resorption]. 2002 Nippon Rinsho pmid:11979946
Udagawa N and Takahashi N [Possible role of receptor activator of NF-kappa B ligand(RANKL) in osteoclast differentiation and function]. 2002 Nippon Rinsho pmid:11979968
Tsuda E [Osteoclastogenesis inhibitory factor (OCIF)/OPG (a novel therapeutic candidate for the treatment of metabolic bone diseases)]. 2002 Nippon Rinsho pmid:11979969
Koshihara Y [Recent progress of bone cell culture system (review)]. 2002 Nippon Rinsho pmid:11979973
Hasegawa T et al. Human periodontal ligament cells derived from deciduous teeth induce osteoclastogenesis in vitro. 2002 Tissue Cell pmid:11989970
Evdokiou A et al. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. 2002 Int. J. Cancer pmid:11992538
Corey E et al. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. 2002 Prostate pmid:11992617
Gruber R et al. Platelet-released supernatants stimulate formation of osteoclast-like cells through a prostaglandin/RANKL-dependent mechanism. 2002 Bone pmid:11996911
de Hooge AS et al. Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-kappa B ligand. 2002 Am. J. Pathol. pmid:12000725
Bosshart H Expression of survival receptors in Hodgkin disease cell lines. 2002 Blood pmid:12001908
Ono K et al. Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. 2002 J. Bone Miner. Res. pmid:12009007
Iida-Klein A et al. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. 2002 J. Bone Miner. Res. pmid:12009011
Jiang Y et al. Bacteria induce osteoclastogenesis via an osteoblast-independent pathway. 2002 Infect. Immun. pmid:12011008
Granchi D et al. Bone cement extracts modulate the osteoprotegerin/osteoprotegerin-ligand expression in MG63 osteoblast-like cells. 2002 Biomaterials pmid:12013183
Li X et al. Prostaglandin receptor EP2 mediates PGE2 stimulated hypercalcemia in mice in vivo. 2002 Prostaglandins Other Lipid Mediat. pmid:12013525
Treuheit MJ et al. Inverse relationship of protein concentration and aggregation. 2002 Pharm. Res. pmid:12033388
Lossdörfer S et al. Immunohistochemical localization of receptor activator of nuclear factor kappaB (RANK) and its ligand (RANKL) in human deciduous teeth. 2002 Calcif. Tissue Int. pmid:12043011

Table of Content